{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:02:41Z","timestamp":1765825361910,"version":"3.48.0"},"reference-count":37,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009128","name":"Research for Patient Benefit Programme","doi-asserted-by":"publisher","award":["NIHR204961"],"award-info":[{"award-number":["NIHR204961"]}],"id":[{"id":"10.13039\/501100009128","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Roche UK","award":["M-GB-00010028"],"award-info":[{"award-number":["M-GB-00010028"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,2,5]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Sickle cell disease (SCD) is one of the most common genetic disorders in the UK, with over 15\u2009000 people affected. Proliferative sickle cell retinopathy (SCR) is a well-described complication of SCD and can result in significant sight loss, although the prevalence in the UK is not currently known. There are currently no national screening guidelines for SCR, with wide variations in the management of the condition across the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The Sickle Eye Project is an epidemiological, cross-sectional, non-interventional study to determine the prevalence of visual impairment due to SCR and\/or maculopathy in the UK. Haematologists in at least 16 geographically dispersed hospitals in the UK linked to participating eye clinics will offer study participation to consecutive patients meeting the inclusion criteria attending the sickle cell clinic. The following study procedures will be performed: (a) best corrected visual acuity with habitual correction and pinhole, (b) dilated slit lamp biomicroscopy and funduscopy, (c) optical coherence tomography (OCT), (d) OCT angiography where available, (e) ultrawide fundus photography, (f) National Eye Institute Visual Function Questionnaire-25 and (g) acceptability of retinal screening questionnaire. The primary outcome is the proportion of people with SCD with visual impairment defined as logarithm of the minimum angle of resolution \u22650.3 in at least one eye. Secondary outcomes include the prevalence of each stage of SCR and presence of maculopathy by age and genotype; correlation of stage of SCR and maculopathy to severity of SCD; the impact of SCR and presence of maculopathy on vision-related quality of life; and the acceptability to patients of routine retinal imaging for SCR and maculopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval was obtained from the South Central\u2013Oxford A Research Ethics Committee (REC 23\/SC\/0363). Findings will be reported through academic journals in ophthalmology and haematology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-082471","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T22:02:18Z","timestamp":1709157738000},"page":"e082471","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Sickle Eye Project: a cross-sectional, non-interventional study of the prevalence of visual impairment due to sickle cell retinopathy and maculopathy in the UK"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-4771","authenticated-orcid":false,"given":"Christiana","family":"Dinah","sequence":"first","affiliation":[{"name":"Ophthalmology, London North West Healthcare NHS Trust, Harrow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Balaskas","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, UK"},{"name":"Institute of Ophthalmology, UCL, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigit","family":"Greystoke","sequence":"additional","affiliation":[{"name":"Royal Victoria Infirmary, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossby","family":"Awadzi","sequence":"additional","affiliation":[{"name":"London North West University Healthcare NHS Trust, Harrow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Beke","sequence":"additional","affiliation":[{"name":"Lived experience expert, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Ahern","sequence":"additional","affiliation":[{"name":"Independent Statistician, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Talks","sequence":"additional","affiliation":[{"name":"Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"2025121510573691000_14.2.e082471.1","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1093\/pubmed\/fdx172","article-title":"How many people have sickle cell disease in the UK","volume":"40","author":"Dormandy","year":"2018","journal-title":"J Public Health (Oxf)"},{"key":"2025121510573691000_14.2.e082471.2","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdt100"},{"key":"2025121510573691000_14.2.e082471.3","unstructured":"Sickle Cell Society . Sickle cell disease: no one is listening. 2021. Available: https:\/\/www.sicklecellsociety.org.\/wpcontent\/uploads\/2021\/11\/No-ones-listening-final.pdf [Accessed 11 Nov 2021]."},{"issue":"Pt 3","key":"2025121510573691000_14.2.e082471.4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/eye.1988.62","article-title":"Patterns of visual loss in untreated sickle cell retinopathy","volume":"2 (Pt 3)","author":"Moriarty","year":"1988","journal-title":"Eye (Lond)"},{"key":"2025121510573691000_14.2.e082471.5","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.64.6.404"},{"key":"2025121510573691000_14.2.e082471.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-716910"},{"key":"2025121510573691000_14.2.e082471.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.05.026"},{"key":"2025121510573691000_14.2.e082471.8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3182364cba"},{"key":"2025121510573691000_14.2.e082471.9","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(71)90429-6"},{"key":"2025121510573691000_14.2.e082471.10","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1974.01010010469002"},{"key":"2025121510573691000_14.2.e082471.11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000512636","article-title":"Sickle cell maculopathy: prevalence, associations and impact on visual acuity","volume":"244","author":"Sahak","year":"2021","journal-title":"Ophthalmologica"},{"key":"2025121510573691000_14.2.e082471.12","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.71.7.540"},{"key":"2025121510573691000_14.2.e082471.13","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1097\/WNO.0000000000001299","article-title":"Binasal visual field defects due to sickle cell maculopathy","volume":"42","author":"Kwok","year":"2022","journal-title":"J Neuroophthalmol"},{"key":"2025121510573691000_14.2.e082471.14","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ajo.2011.03.035","article-title":"Structural and functional correlation in sickle cell retinopathy using spectral domain optical coherence tomography and scanning laser ophthalmoscope microperimetry","volume":"152","author":"Chow","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"2025121510573691000_14.2.e082471.15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0161-6420(83)34537-1","article-title":"A randomized clinical trial of feeder vessel photocoagulation of proliferative sickle cell retinopathy","volume":"90","author":"Jampol","year":"1983","journal-title":"Ophthalmology"},{"key":"2025121510573691000_14.2.e082471.16","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1991.01080030065040"},{"key":"2025121510573691000_14.2.e082471.17","article-title":"Laser therapy for retinopathy in sickle cell disease","volume":"2015","author":"Myint","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121510573691000_14.2.e082471.18","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/bjo.83.7.838","article-title":"Angiogenic factors in human proliferative sickle cell retinopathy","volume":"83","author":"Cao","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"2025121510573691000_14.2.e082471.19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/2474126417738627","article-title":"Intravitreal bevacizumab for proliferative sickle retinopathy: a case series","volume":"2","author":"Cai","year":"2018","journal-title":"J Vitreoretin Dis"},{"key":"2025121510573691000_14.2.e082471.20","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2004.058164"},{"key":"2025121510573691000_14.2.e082471.21","unstructured":"National Institute for Health and Care Excellence (NICE) . Faricimab for treating wet age-related macular degeneration [TA800]. 2023. Available: https:\/\/www.nice.org.uk\/guidance\/ta800"},{"key":"2025121510573691000_14.2.e082471.22","unstructured":"National Institute for Health and Care Excellence (NICE) . Faricimab for treating diabetic macular oedema [TA799]. 2023. Available: https:\/\/www.nice.org.uk\/guidance\/ta799"},{"key":"2025121510573691000_14.2.e082471.23","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41433-018-0127-y","article-title":"A comparison of 23 gauge and 20 gauge vitrectomy for proliferative sickle cell retinopathy \u2013 clinical outcomes and surgical management","volume":"32","author":"Ho","year":"2018","journal-title":"Eye (Lond)"},{"key":"2025121510573691000_14.2.e082471.24","article-title":"Hydroxyurea (Hydroxycarbamide) for sickle cell disease","volume":"4","author":"Nevitt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121510573691000_14.2.e082471.25","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1180242"},{"key":"2025121510573691000_14.2.e082471.26","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bjh.15617","article-title":"Elevated fetal haemoglobin levels are associated with decreased incidence of retinopathy in adults with sickle cell disease","volume":"183","author":"Mian","year":"2018","journal-title":"Br J Haematol"},{"key":"2025121510573691000_14.2.e082471.27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/jamaophthalmol.2020.6525","article-title":"Longitudinal assessment of retinal thinning in adults with and without sickle cell retinopathy using spectral-domain optical coherence tomography","volume":"139","author":"Lim","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"2025121510573691000_14.2.e082471.28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ajo.2018.09.025","article-title":"Clinical and ophthalmic factors associated with the severity of sickle cell retinopathy","volume":"197","author":"Duan","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"2025121510573691000_14.2.e082471.29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2020.11.019","article-title":"Sickle cell maculopathy: microstructural analysis using OCTA and identification of genetic, systemic and biological risk factors","volume":"224","author":"Fares","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"2025121510573691000_14.2.e082471.30","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-316779"},{"key":"2025121510573691000_14.2.e082471.31","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-017-2031-8","article-title":"Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework","volume":"17","author":"Sekhon","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"2025121510573691000_14.2.e082471.32","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-022-07577-3","article-title":"Development of a theory-informed questionnaire to assess the acceptability of healthcare interventions","volume":"22","author":"Sekhon","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"2025121510573691000_14.2.e082471.33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.blre.2019.03.001","article-title":"Sickle cell retinopathy: what we now understand using optical coherence tomography angiography. a systematic review","volume":"35","author":"Leit\u00e3o Guerra","year":"2019","journal-title":"Blood Reviews"},{"key":"2025121510573691000_14.2.e082471.34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ajo.2021.10.030","article-title":"Nonmydriatic ultra-widefield fundus photography in a hematology clinic shows utility for screening of sickle cell retinopathy","volume":"236","author":"Ahmed","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"2025121510573691000_14.2.e082471.35","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jval.2015.08.002","article-title":"A vision \u2018bolt-on\u2019 item could increase the discriminatory power of the EQ-5D index score","volume":"18","author":"Luo","year":"2015","journal-title":"Value Health"},{"key":"2025121510573691000_14.2.e082471.36","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10198-019-01156-w","article-title":"A vision \u2018bolt-on\u2019 increases the responsiveness of EQ-5D: preliminary evidence from a study of cataract surgery","volume":"21","author":"Gandhi","year":"2020","journal-title":"Eur J Health Econ"},{"key":"2025121510573691000_14.2.e082471.37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.5301\/ejo.5000767","article-title":"Risk factors for visual impairment in patients with sickle cell disease in London","volume":"26","author":"Saidkasimova","year":"2016","journal-title":"Eur J Ophthalmol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-082471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:57:45Z","timestamp":1765825065000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-082471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,28]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/bmjopen-2023-082471"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-082471","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}